Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. The companys commercial products include Ampyra (dalfampridine), a treatment to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and tablets, for the management of spasticity; and Qutenza, dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinsons disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.
Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. The companys commercial products include Ampyra (dalfampridine), a treatment to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and tablets, for the management of spasticity; and Qutenza, dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinsons disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.
Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
2
List of Tables 4
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 12
Venture Financing 13
Civitas Therapeutics Raises USD55 Million in Series C Financing 13
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 15
Civitas Therapeutics Secures US$5 Million In Venture Financing 17
Civitas Therapeutics Secures An Additional US$8 Million In Series A Financing Round 17
Partnerships 18
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 18
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 19
Licensing Agreements 20
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 20
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 21
Equity Offering 22
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 22
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 23
Civitas Therapeutics Withdraw IPO for up to USD80 million 25
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 26
Biotie Therapies Completes Private Placement Of Treasury Shares For US$37.4 Million 27
Debt Offering 28
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 28
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 29
Acquisition 31
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 31
Acorda Therapeutics Completes Acquisition Of Neuronex For Up To US$141 Million 32
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 33
Biotie Therapies Acquires Synosia Therapeutics 34
Acorda Therapeutics Inc - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 41
Financial Announcements 42
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 42
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 44
Oct 27, 2016: Acorda Provides Financial and Pipeline Update for Third Quarter 2016 46
Jul 28, 2016: Acorda Provides Financial and Pipeline Update for Second Quarter 2016 48
Apr 28, 2016: Acorda Provides Financial and Pipeline Update for First Quarter 2016 50
Feb 11, 2016: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2015 52
Corporate Communications 54
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 54
Apr 10, 2016: Acorda Announces Departure of Michael Rogers 55
Product News 56
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 56
Product Approvals 57
Aug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United States 57
Clinical Trials 58
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 58
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 59
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 61
Oct 13, 2016: Data from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinsons Disease Published in Science Translational Medicine 63
Apr 20, 2016: Acorda Announces Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinsons Disease Published in Movement Disorders 64
Apr 07, 2016: Phase 2b Data on Inhaled Levodopa CVT-301 Featured in Invited Science Session at American Academy of Neurology (AAN) Annual Meeting 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
List Of Tables
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 12
Civitas Therapeutics Raises USD55 Million in Series C Financing 13
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 15
Civitas Therapeutics Secures US$5 Million In Venture Financing 17
Civitas Therapeutics Secures An Additional US$8 Million In Series A Financing Round 17
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 18
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 19
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 20
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 21
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 22
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 23
Civitas Therapeutics Withdraw IPO for up to USD80 million 25
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 26
Biotie Therapies Completes Private Placement Of Treasury Shares For US$37.4 Million 27
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 28
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 29
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 31
Acorda Therapeutics Completes Acquisition Of Neuronex For Up To US$141 Million 32
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 33
Biotie Therapies Acquires Synosia Therapeutics 34
Acorda Therapeutics Inc, Key Competitors 38
Acorda Therapeutics Inc, Key Employees 39
Acorda Therapeutics Inc, Subsidiaries 40
List Of Figures
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
RELATED REPORTS
Acorda Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report
Acorda Therapeutics, Inc. - Strategy, SWOT and Corporate Finance ReportAcorda Therapeutics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report
View ReportAcorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review
Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by
View ReportAnika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2021 Update
Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical and veterinary applications. Its major
View ReportChinook Therapeutics Inc (KDNY) - Financial and Strategic SWOT Analysis Review
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
